IBRXライブシグナル | Getagraph.comで利益を最大化

買う 107025 min ago

@ $4.52

発行日: 15 2月 2024 @ 03:58

リターン: 62.79%

前回のシグナル: 2月 14 - 23:30

前回のシグナル: 売る

リターン: 4.24 %

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	39.08M
平均出来高	5.40M
時価総額	4.95B
EPS	$-0.350 ( 2024-03-20 )
次の収益日	( $-0.160 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.39
ATR14	$0.117 (1.59%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	Simon Barry J.	Buy	159 146	Stock Option (right to buy)
2024-02-22	Simon Barry J.	Buy	45 731	Restricted Stock Units
2024-02-22	Lauer Regan J	Buy	42 439	Stock Option (right to buy)
2024-02-22	Lauer Regan J	Buy	12 195	Restricted Stock Units
2024-02-22	Sachs David C.	Buy	424 390	Stock Option (right to buy)

INSIDER POWER
99.24
Last 97 transactions
Buy: 228 380 025 \| Sell: 921 083

ボリューム相関

長: 0.53 (weak)

短: -0.15 (neutral)

Signal:(48.073) Neutral

ImmunityBio, Inc. 相関

10 最も正の相関
SIRI	0.928
RGF	0.928
FGBI	0.925
AROW	0.921
ALRS	0.92
GNTY	0.92
CBNK	0.915
GSMG	0.914
GOOD	0.906
ALLK	0.906

10 最も負の相関
RIVE	-0.933
DSEY	-0.93
DUOL	-0.927
AMPH	-0.926
RAM	-0.919
INTA	-0.919
PLYA	-0.918
ALTR	-0.91
DAIO	-0.909
MLTX	-0.907

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

ImmunityBio, Inc. 相関 - 通貨/商品

0.51
( weak )

0.64
( weak )

0.00
( neutral )

0.23
( neutral )

0.04
( neutral )

0.83
( strong )

ImmunityBio, Inc. 財務諸表

Annual	2023
収益:	$622 000
総利益:	$-17.89M (-2 876.21 %)
EPS:	$-1.150

FY	2023
収益:	$622 000
総利益:	$-17.89M (-2 876.21 %)
EPS:	$-1.150

FY	2022
収益:	$240 000
総利益:	$-23.95M (-9 980.00 %)
EPS:	$-1.040

FY	2021
収益:	$934 000
総利益:	$0.00 (0.00 %)
EPS:	$-0.893

Financial Reports:

No articles found.

ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.